Intra-Cellular Stock Market Sentiment

ITCI
 Stock
  

USD 57.08  1.23  2.11%   

Intra-Cellular investor sentiment overview provides quick insight into current market opportunities from investing in Intra-Cellular Ther. The current market sentiment together Intra-Cellular Ther's historical and current headlines can help investors to time the market. Many technical investors use Intra-Cellular Ther stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Please see Intra-Cellular Ther Hype Analysis, Intra-Cellular Ther Correlation and Intra-Cellular Ther Performance.
  
Refresh
Intra-Cellular Ther stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Intra-Cellular daily returns and investor perception about the current pice of Intra-Cellular Ther as well as its diversification or hedging effects on your existing portfolios.

Intra-Cellular Latest Sentiment Indicators

200 Day MA
49.04
Short Percent
0.038
Short Ratio
3.14
Shares Short Prior Month
3.1 M
50 Day MA
55.23
52 Week Low
28.4
Shares Short
3.6 M

Intra-Cellular Ther Current Investor Sentiment

Investor biases related to Intra-Cellular Ther's public news can be used to forecast risks associated with investment in Intra-Cellular. The trend in average sentiment can be used to explain how an investor holding Intra-Cellular can time the market purely based on public headlines and social activities around Intra-Cellular Ther. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Intra-Cellular Ther's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intra-Cellular Ther's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intra-Cellular Ther's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Intra-Cellular Ther.

Intra-Cellular Ther Maximum Pain Price across 2022-07-15 Option Contracts

Intra-Cellular Ther's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Intra-Cellular Ther close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Intra-Cellular Ther's options.
over a week ago at www.medscape.com         
Transdermal Med May Directly Target Hostility in Schizophrenia - Medscape
news
over a week ago at www.benzinga.com         
INVESTIGATION REMINDER The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. wi...
benzinga news
over a week ago at www.marketscreener.com         
INVESTIGATION ALERT The Schall Law Firm Encourages Investors in Intra-Cellular Therapies, Inc. with ...
news
over two weeks ago at seekingalpha.com         
ZIM Integrated Stock New Shipping Act And Long-Term Profitability - Seeking Alpha
seekingalpha News
over two weeks ago at finance.yahoo.com         
Acquisition by Salas Eduardo Rene of 16757 shares of Intra-Cellular Ther subject to Rule 16b-3
Yahoo News
over three weeks ago at www.tipranks.com         
Is There Light at the End of the Tunnel for DiDi - TipRanks
news
over three weeks ago at www.businessinsider.in         
New diabetes drug significant in fight against obesity, reveals new study - Business Insider India
businessinsider News
over three weeks ago at www.marketscreener.com         
Soligenix, Inc. - Key Binding Characteristics of Dusquetide to Important Intracellular Protein Ident...
news
over three weeks ago at industrialit.com.au         
Bipolar Disorder Therapeutics Drugs Market Size And Growth Key Players GSK, Intra-Cellular Therapies...
news
over a month ago at virologyj.biomedcentral.com         
Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21proteasomal pathway -...
news
over a month ago at www.nature.com         
EF-hand protein, EfhP, specifically binds Ca2 and mediates Ca2 regulation of virulence in a human pa...
news
over a month ago at www.nature.com         
ZnO size and shape effect on antibacterial activity and cytotoxicity profile Scientific Reports - Na...
news
over a month ago at www.fwbusiness.com         
What Stocks To Buy This Week 4 Biotech Stocks To Know - FW Business
news
over a month ago at www.macroaxis.com         
Exercise or conversion by Joel Marcus of 14189 shares of Intra-Cellular Ther subject to Rule 16b-3
Macroaxis News
over a month ago at www.fool.com         
Why Intra-Cellular Therapies Stock Rose 21.4 percent This Week - The Motley Fool
fool News
There is far too much social signal, news, headlines, and media speculation about Intra-Cellular Ther that is available to investors today. That information is available publicly through Intra-Cellular media outlets and privately through word of mouth or via Intra-Cellular internal channels. However, regardless of the origin, that massive amount of Intra-Cellular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intra-Cellular Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intra-Cellular Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intra-Cellular Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intra-Cellular Ther alpha.

Intra-Cellular Ther Performance against DOW

 Price Growth (%)  
      Timeline 
1
Acquisition by Van Nostrand Robert L of 126 shares of Intra-...04/04/2022
2
Sale by Rory Riggs of 20686 shares of Intra-Cellular Ther04/07/2022
3
Exercise or conversion by Mark Neumann of 86348 shares of In...04/08/2022
4
Acquisition by Salas Eduardo Rene of 20000 shares of Intra-C...04/21/2022
5
Financial Statements04/25/2022
6
Prioritization of autoimmune disease-associated genetic vari...05/05/2022
7
EPS Reported05/10/2022
8
Intra-Cellular Therapies Stock Clears Technical Benchmark, H...05/11/2022
9
Exercise or conversion by Joel Marcus of 14189 shares of Int...05/13/2022
10
Anti-L1 antibody-bound HPV16 pseudovirus is degraded intrace...05/26/2022
11
New diabetes drug significant in fight against obesity, reve...06/06/2022
12
Filing06/13/2022
13
ZIM Integrated Stock New Shipping Act And Long-Term Profitab...06/14/2022
14
Transdermal Med May Directly Target Hostility in Schizophren...06/22/2022
Please see Intra-Cellular Ther Hype Analysis, Intra-Cellular Ther Correlation and Intra-Cellular Ther Performance. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.